Alan Rosling reflects on the Indian Supreme Court's 2013 ruling where Novartis lost the right to a patent for the cancer drug Gleevec.

Alan Rosling is an entrepreneur and strategic adviser who has had a deep engagement with India over the past thirty-five years. He is co-founder of ECube, an investment manager dedicated to raising standards of environmental social and governance compliance. He cofounded Kiran Energy after leaving the Tata Group, where he was the first non-Indian Executive Director of Tata Sons (the holding company of the Tata Group), charged with internationalization of the company. His earlier career included general management, strategy and banking, and three years as a Special Adviser to the British Prime Minister in the Policy Unit at 10 Downing Street. Educated at Downing College, Cambridge, and Harvard Business School, Alan now lives in Hong Kong but is in India frequently. He was awarded a CBE (an honor for a distinguished contribution to Britain) in 2014.

Insights

Novartis in India: A Patent War